Trial · NCT00333359
Results by group270
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 270
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in the International Restless Legs Syndrome Rating Scale (IRLS) at Week 52 Using Observed Case (OC) | Naïve; 1200 mg GEn | -16.3 | Standard Deviation 8.23 | points on a scale | |
| Change From Baseline in the International Restless Legs Syndrome Rating Scale (IRLS) at Week 52 Using Observed Case (OC) | Non-naïve; 1200 mg GEn | -17.0 | Standard Deviation 8.20 | points on a scale | |
| Change From Baseline in the International Restless Legs Syndrome Rating Scale (IRLS) at Week 52 Using Observed Case (OC) | All Participants; 1200 mg GEn | -16.8 | Standard Deviation 8.21 | points on a scale | |
| Number of Participants Classified as Responders to Treatment on the Investigator-rated Clinical Global Impressions of Improvement (CGI-I) at Each Visit Using OC | Naïve; 1200 mg GEn | Week 0, n=197, 376, 573 | 84 | participants | |
| Number of Participants Classified as Responders to Treatment on the Investigator-rated Clinical Global Impressions of Improvement (CGI-I) at Each Visit Using OC | Non-naïve; 1200 mg GEn | Week 0, n=197, 376, 573 | 300 | participants | |
| Number of Participants Classified as Responders to Treatment on the Investigator-rated Clinical Global Impressions of Improvement (CGI-I) at Each Visit Using OC | All Participants; 1200 mg GEn | Week 0, n=197, 376, 573 | 384 | participants | |
| Number of Participants Classified as Responders to Treatment on the Investigator-rated Clinical Global Impressions of Improvement (CGI-I) at Each Visit Using OC | Naïve; 1200 mg GEn | Week 1, n=185, 363, 548 | 152 | participants | |
| Number of Participants Classified as Responders to Treatment on the Investigator-rated Clinical Global Impressions of Improvement (CGI-I) at Each Visit Using OC | Non-naïve; 1200 mg GEn | Week 1, n=185, 363, 548 | 294 | participants | |
| Number of Participants Classified as Responders to Treatment on the Investigator-rated Clinical Global Impressions of Improvement (CGI-I) at Each Visit Using OC | All Participants; 1200 mg GEn | Week 1, n=185, 363, 548 | 446 | participants | |
| Number of Participants Classified as Responders to Treatment on the Investigator-rated Clinical Global Impressions of Improvement (CGI-I) at Each Visit Using OC | Naïve; 1200 mg GEn | Week 4, n=171, 354, 525 | 143 | participants | |
| Number of Participants Classified as Responders to Treatment on the Investigator-rated Clinical Global Impressions of Improvement (CGI-I) at Each Visit Using OC | Non-naïve; 1200 mg GEn | Week 4, n=171, 354, 525 | 308 | participants | |
| Number of Participants Classified as Responders to Treatment on the Investigator-rated Clinical Global Impressions of Improvement (CGI-I) at Each Visit Using OC | All Participants; 1200 mg GEn | Week 4, n=171, 354, 525 | 451 | participants | |
| Number of Participants Classified as Responders to Treatment on the Investigator-rated Clinical Global Impressions of Improvement (CGI-I) at Each Visit Using OC | Naïve; 1200 mg GEn | Week 12, n=150, 324, 474 | 133 | participants | |
| Number of Participants Classified as Responders to Treatment on the Investigator-rated Clinical Global Impressions of Improvement (CGI-I) at Each Visit Using OC | Non-naïve; 1200 mg GEn | Week 12, n=150, 324, 474 | 297 | participants | |
| Number of Participants Classified as Responders to Treatment on the Investigator-rated Clinical Global Impressions of Improvement (CGI-I) at Each Visit Using OC | All Participants; 1200 mg GEn | Week 12, n=150, 324, 474 | 430 | participants | |
| Number of Participants Classified as Responders to Treatment on the Investigator-rated Clinical Global Impressions of Improvement (CGI-I) at Each Visit Using OC | Naïve; 1200 mg GEn | Week 24, n=138, 305, 443 | 126 | participants | |
| Number of Participants Classified as Responders to Treatment on the Investigator-rated Clinical Global Impressions of Improvement (CGI-I) at Each Visit Using OC | Non-naïve; 1200 mg GEn | Week 24, n=138, 305, 443 | 275 | participants | |
| Number of Participants Classified as Responders to Treatment on the Investigator-rated Clinical Global Impressions of Improvement (CGI-I) at Each Visit Using OC | All Participants; 1200 mg GEn | Week 24, n=138, 305, 443 | 401 | participants | |
| Number of Participants Classified as Responders to Treatment on the Investigator-rated Clinical Global Impressions of Improvement (CGI-I) at Each Visit Using OC | Naïve; 1200 mg GEn | Week 36, n=132, 281, 413 | 120 | participants | |
| Number of Participants Classified as Responders to Treatment on the Investigator-rated Clinical Global Impressions of Improvement (CGI-I) at Each Visit Using OC | Non-naïve; 1200 mg GEn | Week 36, n=132, 281, 413 | 260 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00333359/results